Navigation Links
Mylan Announces Clarinex(R) Settlement Agreement
Date:4/8/2009

PITTSBURGH, April 8 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced the settlement of all patent litigation relating to Desloratadine Tablets, 5 mg, the generic version of Schering- Plough's Clarinex(R) allergy medication. This litigation has been pending in the U.S. District Court of New Jersey since September 2006.

Pursuant to the settlement, Mylan will have the right to market Desloratadine Tablets, 5 mg, in the U.S. on July 1, 2012, or earlier in certain circumstances, provided that the U.S. Food and Drug Administration (FDA) approves Mylan's abbreviated new drug application (ANDA). Mylan's product may be the prescription form or an over-the-counter version, depending on the status of Clarinex at the time. Additional terms of the settlement are confidential, and the agreement is subject to review by the Department of Justice and the Federal Trade Commission.

Desloratadine Tablets, 5 mg, had U.S. sales of approximately $284 million for the 12 months ending Dec. 31, 2008, according to IMS Health.

This press release includes statements that constitute "forward-looking statements," including with regard to the settlement and marketing of the product. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: any legal or regulatory challenges to the settlement; strategies by competitors or other third parties to delay or prevent product introductions; risks inherent in legal and regulatory processes; and the other risks detailed in the company's periodic filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generics and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Announces Intention to Purchase Remaining Interest in Matrix Laboratories and Delist Matrix from Indian Stock Exchanges
2. Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for First Generic, Heat-Stable Version of HIV Protease Inhibitor
3. Mylans Matrix Receives WHO Approval for First Generic, Heat-Stable Version of HIV Protease Inhibitor
4. Mylan Announces Transition of Chief Financial Officer
5. Mylan Vice Chairman and CEO Robert J. Coury to Ring NASDAQ Stock Market Opening Bell
6. Mylan Schedules Fourth Quarter Financial Results Conference Call and Live Webcast
7. Mylan Receives FDA Approval for First-to-File Generic Depakote(R) ER
8. Mylan Declares Quarterly Preferred Stock Dividend
9. Mylan Receives Final FDA Approvals for Generic Versions of Lamictal(R) Tablets and Lamictal(R) CD
10. Mylan Receives Final FDA Approval for Generic Version of Prilosec(R) Delayed-Release Capsules, 40 mg
11. U.S. Patent and Trademark Office Issues Mylans Specialty Division, Dey L.P., Three Additional Patents Protecting Perforomist(R) Inhalation Solution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Los Angeles, California (PRWEB) , ... January 19, ... ... at the hands of a doctor who administered fillers that resulted in severe ... her unprecedented case was taken on by doctors at UCLA Medical Center, who ...
(Date:1/19/2017)... CA (PRWEB) , ... January 19, 2017 , ... ... Tranquility acoustic and privacy panel system. , The Tranquility privacy panel system ... a collaborative office environment. Tranquility panels help reduce noise and provide the visual ...
(Date:1/19/2017)... ... January 19, 2017 , ... Sam & Associates Insurance Agency, a full service ... in the California Bay Area, is launching a charity drive to raise awareness of ... disease is the primary killer of adult men and women in America, and is ...
(Date:1/19/2017)... ... January 19, 2017 , ... For the third ... New Jersey and the surrounding area, is inaugurating a charity event to ... commonly known as Lou Gehrig's disease or motor neurone disease, is a deadly ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... the 2017 Spring Create Real Impact contest from Impact Teen Drivers and California ... http://www.createrealimpact.com . , Educational grants totaling $15,000 will be awarded for ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... Research and Markets has announced the addition of the ... Opportunity Analysis and Industry Forecast, 2014-2022" report to their offering. ... Vital signs monitoring market size ... million by 2022, growing at a CAGR of 5.8% from 2016 to ... leading regional market in global vital signs monitoring devices industry. The blood ...
(Date:1/18/2017)... -- Adaptive Sound Technologies, Inc. (ASTI), the leading supplier of ... Place Nashville/Downtown to deliver the best sleep experience for ... in over two hundred of its guest rooms. ... having a great stay is sleeping well," said ... "We,re pleased to be able to offer our guests ...
(Date:1/18/2017)... FALLS, N.J. , Jan. 18, 2017   ... ), a biotechnology company specializing in the development and ... of damaged tissues and organs, recently reported the Company,s ... milestones for 2017. As the Company described ... has been a year of substantial accomplishments. The Company,s ...
Breaking Medicine Technology: